By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Abraxis BioScience, Inc. (Acquired by Celgene Corporation) 

Press releases archived for reference only.
11755 Wilshire Boulevard, 20th Floor
Los Angeles  California  90025  U.S.A.
Phone: Fax:



Company News
Ex-Abraxis BioScience, Inc. Cancer Researcher-Turned-Billionaire Starts New Company 1/29/2013 8:10:14 AM
Celgene (Summit, New Jersey) (CELG) Completes Acquisition of Abraxis BioScience, Inc. 10/15/2010 11:03:55 AM
Celgene Corporation (CELG) and Abraxis BioScience, Inc. Announce Shareholder Vote in Favor of Merger 10/14/2010 7:57:35 AM
Antitope Announces EpiScreen Collaboration with Abraxis BioScience, Inc. 9/29/2010 1:27:33 PM
Celgene Corporation (CELG)/Abraxis BioScience, Inc. Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period 8/4/2010 9:52:00 AM
Abraxis BioScience, Inc. and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand 7/29/2010 8:04:43 AM
Abraxis BioScience, Inc.'s ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer 7/23/2010 10:58:53 AM
Celgene (CELG) to Buy Abraxis BioScience, Inc. for $2.9 Billion 6/30/2010 6:36:12 AM
Abraxis BioScience, Inc. Release: American Society of Clinical Oncology Presentations Offer New Insights into Role of nab(R)-Chemotherapy Based Breast Cancer Chemotherapy Treatment 6/8/2010 9:41:32 AM
Abraxis BioScience, Inc. Release: Among the Toughest Cancers to Treat, New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma 6/8/2010 9:35:50 AM